Intravenous Dofetilide Dosing Guided by QT and Creatinine Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dofetilide, a Class III antiarrhythmic agent, is currently approved only for oral administration and not for parenteral use, limiting its application in situations where oral administration is impractical or not recommended, such as gastrointestinal conditions affecting drug absorption or intensive care settings.
Innovation Solution
Intravenous administration of dofetilide and other anti-arrhythmics, such as sotalol, amiodarone, ibutilide, dronedarone, procainamide, flecainide, or propafenone, is provided through formulations suitable for parenteral use, including sterile aqueous or non-aqueous solutions, with dosing adjusted based on QT interval and creatinine clearance to treat cardiovascular conditions like atrial fibrillation and atrial flutter.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If dofetilide is administered orally, then it can be used to treat atrial fibrillation and atrial flutter, but it cannot be used in patients with gastrointestinal conditions affecting drug absorption or in intensive care settings where oral administration is impractical
Solution Approach 1:
The patent changes the administration parameter from oral to intravenous route, enabling the drug to be used in patients with gastrointestinal conditions affecting absorption. The intravenous formulation allows direct delivery of dofetilide into the bloodstream, bypassing the gastrointestinal tract entirely, thus resolving the contradiction between administration flexibility and absorption reliability.
2Adaptability or versatility
If intravenous administration of dofetilide is implemented, then it can be used in intensive care settings and for patients with gastrointestinal conditions, but the drug must be formulated in sterile aqueous or non-aqueous solutions requiring specialized preparation
Solution Approach 1:
The patent introduces sterile aqueous or non-aqueous solutions as intermediary carriers to enable intravenous administration. These formulations act as mediators that allow the drug to be delivered safely and effectively through parenteral routes, expanding the indication range to include intensive care settings and patients with gastrointestinal conditions while managing the formulation complexity through standardized preparation protocols.
3Reliability
If dosing is adjusted based on QT interval and creatinine clearance, then patient-specific pharmacokinetics can be optimized, but the administration protocol becomes more complex requiring continuous monitoring and adjustment
Solution Approach 1:
The patent implements feedback mechanisms by continuously monitoring QT interval and adjusting the dosing rate accordingly. The system also incorporates creatinine clearance measurements to optimize pharmacokinetics. This feedback approach ensures dosing accuracy while managing protocol complexity through structured monitoring intervals and adjustment criteria that balance patient safety with operational feasibility.
Data Source
AI summary
Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg/kg bodyweight over a duration of up to 60 minutes can be administered and/or a maintenance dose of 0.1 to 10 μg/kg/hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and/or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and/or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.